Biomaterial derived dendritic cells for regenerative medicine

This project will establish a commercially viable, regenerative biomaterial-based method for effective, reduced-cost and clinically feasible culture of immune cells for immune cell therapies. Argan Biomedical Technologies inc, partnering with the Sefton lab at UofT, has developed technology that uses regenerative synthetic biomaterials to reduce the use of expensive and otherwise problematic biological components used in typical culture of immune cells for immune cell therapy. The technology leverages the Sefton lab’s extensive experience with biomaterials; the immune cells generated appear more effective than those generated through conventional means. Here we will use the opportunity provided by MITACS to generate proof-of-concept data showing that these cells are effective and viable for clinical scale use, and that they are applicable for use from immunosuppression alternatives for transplantation to cancer therapeutics.

Faculty Supervisor:

Michael Sefton

Student:

Partner:

Argan

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Toronto

Program: